7974 related articles for article (PubMed ID: 2357766)
1. Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
Narita T; Yaguchi S; Komatsu T; Takase M; Hoshino A; Inaba M; Tsukagoshi S
Cancer Chemother Pharmacol; 1990; 26(3):193-7. PubMed ID: 2357766
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activities and schedule dependence of orally administered MST-16, a novel derivative of bis(2,6-dioxopiperazine).
Narita T; Koide Y; Yaguchi S; Kimura S; Izumisawa Y; Takase M; Inaba M; Tsukagoshi S
Cancer Chemother Pharmacol; 1991; 28(4):235-40. PubMed ID: 1879040
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and antitumor properties of N1-acyloxymethyl derivatives of bis(2,6-dioxopiperazines).
Cai JC; Shu HL; Tang CF; Komatsu T; Matsuno T; Narita T; Yaguchi S; Koide Y; Takase M
Chem Pharm Bull (Tokyo); 1989 Nov; 37(11):2976-83. PubMed ID: 2632042
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of novel ailanthone derivatives in vitro and in vivo.
Kato T; Suzumura Y; Fukushima M; Honda T; Nakanishi T; Noguchi T
Anticancer Res; 1988; 8(4):573-9. PubMed ID: 3178149
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity on murine tumors of a novel antitumor benzoylphenylurea derivative, HO-221.
Nakajima T; Masuda H; Okamoto T; Watanabe M; Yokoyama K; Yamada N; Fujimoto S; Tsukagoshi S; Taguchi T
Cancer Chemother Pharmacol; 1991; 28(5):351-6. PubMed ID: 1914078
[TBL] [Abstract][Full Text] [Related]
9. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
10. In vivo antitumor activity and in vitro cytotoxic properties of bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride.
Berners-Price SJ; Mirabelli CK; Johnson RK; Mattern MR; McCabe FL; Faucette LF; Sung CM; Mong SM; Sadler PJ; Crooke ST
Cancer Res; 1986 Nov; 46(11):5486-93. PubMed ID: 3756897
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antitumor activity of 9-acyloxyellipticines.
Harada N; Ozaki K; Oda K; Nakanishi N; Ohashi M; Hashiyama T; Tsujihara K
Chem Pharm Bull (Tokyo); 1997 Jul; 45(7):1156-62. PubMed ID: 9246749
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
Jurd L; Narayanan VL; Paull KD
J Med Chem; 1987 Oct; 30(10):1752-6. PubMed ID: 2821258
[TBL] [Abstract][Full Text] [Related]
13. [A novel antitumor agent, sobuzoxane (MST-16)].
Tsukagoshi S
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1089-97. PubMed ID: 8002628
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of a soluble etoposide analog, BMY-40481-30.
Rose WC; Basler GA; Trail PA; Saulnier M; Crosswell AR; Casazza AM
Invest New Drugs; 1990; 8 Suppl 1():S25-32. PubMed ID: 2380014
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
16. Phase II study: treatment of non-Hodgkin's lymphoma with an oral antitumor derivative of bis(2,6-dioxopiperazine).
Ohno R; Yamada K; Hirano M; Shirakawa S; Tanaka M; Oguri T; Kodera Y; Mitomo Y; Ikeda Y; Yokomaku S
J Natl Cancer Inst; 1992 Mar; 84(6):435-8. PubMed ID: 1538420
[TBL] [Abstract][Full Text] [Related]
17. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice.
Ueda H; Manda T; Matsumoto S; Mukumoto S; Nishigaki F; Kawamura I; Shimomura K
J Antibiot (Tokyo); 1994 Mar; 47(3):315-23. PubMed ID: 8175484
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
19. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy.
Yoshida M; Maehara Y; Sugimachi K
Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of IST-622, a novel synthetic derivative of chartreusin, against murine and human tumor lines following oral administration.
Tashiro T; Kon K; Yamamoto M; Yamada N; Tsuruo T; Tsukagoshi S
Cancer Chemother Pharmacol; 1994; 34(4):287-92. PubMed ID: 8033294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
